NEW MENAQ7® VITAMIN K2 CARDIOVASCULAR STUDY PUBLISHES

Vascular Diseases and Therapeutics publishes 1-year study confirming MenaQ7® Vitamin K2 as MK-7 supplementation improves vascular health Oslo, Norway and Edison, NJ (7 July 2020) — A new one-year clinical trial has just been published showing that a daily nutritional...

VITAMIN K2 NEEDS RDI: NEW PAPER

NattoPharma research partners publish important review paper clearly identifying the need for a Vitamin K2-specific RDI Oslo, Norway and Edison, NJ (24 June 2020) — Widespread Vitamin K deficiency has had an indelible impact on global cardiovascular and bone health,...

NEW STUDY – VITAMIN K2 LOWERS CORONARY HEART DISEASE RISK

New prospective cohort study identifies K2 as cardio-protective while K1 intakes are not. Oslo, Norway and Edison, NJ (28 May 2020) — The British Medical Journal recently published an observational study that examined the association between intakes of vitamins K1 and...

NEW STUDY: VITAMIN K1 NOT CARDIO-PROTECTIVE

Vitamin K2 supports heart health through impact on Matrix Gla Protein; K1 has no effect.   Oslo, Norway and Edison, NJ (XX June 2019) — Vitamin K is not a single vitamin – it is a family of vitamins comprised of vitamins K1 (phylloquinone) and K2 (menaquinone)....